Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits

BACKGROUND: Treatment of proliferative GN with monoclonal Ig deposits (PGNMID) is not established. A monoclonal anti-CD38 antibody (daratumumab) is effective in treating multiple myeloma. Abnormal plasma cell clones may play a role in the pathogenesis of PGNMID. METHODS: We evaluated daratumumab’s s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zand, Ladan, Rajkumar, S. Vincent, Leung, Nelson, Sethi, Sanjeev, El Ters, Mireille, Fervenza, Fernando C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Nephrology 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259683/
https://www.ncbi.nlm.nih.gov/pubmed/33685975
http://dx.doi.org/10.1681/ASN.2020101541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259683/
https://www.ncbi.nlm.nih.gov/pubmed/33685975
http://dx.doi.org/10.1681/ASN.2020101541

Ejemplares similares